Zimmer price target raised to $131 from $110 at Canaccord Canaccord raised its price target on Zimmer Holdings to $131 from $110 to reflect the acquisition of Biomet. The firm sees a massive new knee product cycle and believes Zimmer is positioned solidly in the global musculoskeletal and OrthoRecon industry. Canaccord maintains its Buy rating on the stock.
News For ZMH From The Last 14 Days
Check below for free stories on ZMH the last two weeks.
Zimmer should be bought on any weakness from Q2 results, says RBC Capital RBC Capital believes that consensus Q2 recon estimates for Zimmer may be "a bit optimistic," but the firm thinks that investors already partially anticipate a miss on that metric The firm recommends buying the stock on any weakness associated with Q2 results, as it thinks the company's valuation is favorable, given its growth outlook. RBC Capital keeps a $120 price target and Outperform rating on the shares.